Taken together these data demonstrate that patients with RCC have increased levels of sTREM-1 in their blood compared with healthy donors and that tumor-associated Trem1 correlates with high disease stage, primary tumor size, and poor outcomes in RCC. This evidence concerns the gene TREM1 and renal cell carcinoma.